Topotecan in combination with carboplatin: Phase I trial evaluation of two treatment schedules

Annals of Oncology

Volumn 13, Issue 3, 2002, Pages 399-402

  Simpson, A B ^a   Calvert, P M ^a   Sludden, J A ^a   Boddy, A V ^a   Griffin, M J ^b   Schatzlein A ^b   Wilson, P ^a   Fishwick, K ^a   Wheatley, A ^b   Ross, G A ^a   Calvert, A H ^a   Twelves, C J ^b  

^a SmithKline Beecham ^*

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Carboplatin; Chemotherapy; Topotecan

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG INFUSION; ENDOMETRIUM CANCER; FATIGUE; FEMALE; HUMAN; LUNG CANCER; MALE; MELANOMA; MESOTHELIOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG SCREENING; EVALUATION; HEMATOLOGIC DISEASE; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SURVIVAL RATE; TOPOTECAN;

EID: 0036018902     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf041     Document Type: Article

References (11)

1. Combination regimens with topotecan in animal tumor models
2. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study
3. Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence
4. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma
5. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
6. Pharmacokinetics of cis-diamine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function
7. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
8. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine
9. Phase I and pharmacologic study of topotecan in patients with impaired renal function
10. A clinical phase I trial of topotecan in combination with carboplatin in patients with advanced solid tumors
11. Reverse schedule topotecan and carboplatin in relapsed ovarian cancer: A phase I/II dose-ranging study